Ascletis Pharma Inc. (ASCLETIS-B) released its Monthly Return for Equity Issuers covering March 2026, confirming a month of capital stability with no new share issuance or treasury-share movements.

Authorised and Issued Share Capital • Authorised share capital remained unchanged at 7.00 billion ordinary shares with a par value of USD 0.0001 each, equivalent to USD 0.70 million. • Issued shares (excluding treasury) closed the month at 1.06 billion, while treasury shares stood at 7.08 million, keeping total issued shares at 1.07 billion. • No additions or cancellations were recorded during the month.

Public Float Status • Ascletis affirmed compliance with the Main Board’s minimum public-float threshold of 25%, ensuring continued alignment with Hong Kong Listing Rules.

Equity Incentive Schemes • The 2019 Share Option Scheme saw 15,000 options cancelled, reducing its outstanding balance to 6.75 million. • The 2025 Share Option Scheme remained unchanged with 5.47 million options outstanding. • Aggregate outstanding options across both schemes totalled 12.22 million, with capacity for up to 36.18 million additional shares to be granted or issued under existing mandates. • No options were exercised; consequently, no shares were issued and no proceeds were raised during the month.

Share Repurchases Pending Cancellation • The company retains 5.79 million shares repurchased in 2024-2025 that have not yet been cancelled (0.80 million from April 2025 and 4.99 million from October-December 2025). March 2026 recorded no new repurchases or cancellations.

Other Instruments • The issuer reported no outstanding warrants, convertible securities or Hong Kong Depositary Receipts.

Governance • The monthly return was submitted on 8 April 2026, signed by Company Secretary Chung Ming Fai.

Bottom line: Ascletis-B’s March filing highlights a steady capital structure, unchanged share count and full adherence to public-float requirements, underscoring disciplined equity management ahead of any future corporate actions.